sefulness of Complete Blood Count and Ferritin Measurement in the Anemia Diagnosis in Pregnancy

Phase 3

Recruiting

• Conditions: Anemia; C15.378.071.196.300; G08.686.785.760.769

• Registration Number: RBR-237wbg
• Lead Sponsor: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-01-03
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: recruiting
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Hemoglobin concentration at least 0.7 and below 11.0 g/dL. Gestational age between 12 and 32 weeks of pregnancy. Low-risk pregnancy.

Exclusion Criteria

Hipersensibility or intolerability to ferros sulfate. Mental disease that precludes to understand the intervention. Unknowing the gestacional age. Another cause of anemia: sickel cell disease, talassemia, spherocytosis, autoimmune hemolytic anemia, leukemias, anemia of crônic disease. Sistemic infeccious diseases: human immunedeficiency virus, siphilis, urinary infeccion, leucocytosis. Tobacco, alcohol or other drugs use.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
It is expected that the responsiveness to therapeutic test with oral iron (final diagnosis of functional iron deficiency) achieves an increase of at least 0.55 Z-score of haemoglobin after a minimum of 4 weeks treatment and an intake of at least 1200 mg of elemental iron (effective total dose). The primary outcome will be measured by the difference between the pre-treatment haemoglobin concentration (erythrogram collected on time-zero) and the post-treatment haemoglobin concentration (erythrogram collected on monthly revaluations 1, 2 or 3).